| 1,2,4-trimethylbenzene | decreases expression | EXP | | 6480464 | pseudocumene results in decreased expression of EGLN3 protein | CTD | PMID:17337753 |
| 17alpha-ethynylestradiol | multiple interactions | ISO | RGD:732653 | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of EGLN3 mRNA | CTD | PMID:17942748 |
| 17alpha-ethynylestradiol | increases expression | EXP | | 6480464 | Ethinyl Estradiol results in increased expression of EGLN3 mRNA | CTD | PMID:15576828 PMID:15901920 |
| 17alpha-ethynylestradiol | increases expression | EXP | | 6480464 | Ethinyl Estradiol results in increased expression of EGLN3 mRNA | CTD | PMID:15901920 PMID:15576828 |
| 17alpha-ethynylestradiol | affects expression | EXP | | 6480464 | Ethinyl Estradiol affects the expression of EGLN3 mRNA | CTD | PMID:16079270 |
| 17beta-estradiol | decreases expression | ISO | RGD:732652 | 6480464 | Estradiol results in decreased expression of EGLN3 mRNA | CTD | PMID:20106945 |
| 17beta-estradiol | decreases expression | ISO | RGD:732652 | 6480464 | Estradiol results in decreased expression of EGLN3 mRNA | CTD | PMID:20106945 PMID:21632981 |
| 17beta-estradiol | increases expression | ISO | RGD:732652 | 6480464 | Estradiol results in increased expression of EGLN3 mRNA | CTD | PMID:19619570 |
| 17beta-estradiol | multiple interactions | ISO | RGD:732652 | 6480464 | [Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of EGLN3 mRNA | CTD | PMID:19619570 |
| 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:732653 | 6480464 | [Tetrachlorodibenzodioxin co-treated with Ethinyl Estradiol] results in increased expression of EGLN3 mRNA | CTD | PMID:17942748 |
| 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:732653 | 6480464 | Tetrachlorodibenzodioxin affects the expression of EGLN3 mRNA | CTD | PMID:21570461 |
| 2,3,7,8-tetrachlorodibenzodioxine | affects expression | ISO | RGD:732652 | 6480464 | Tetrachlorodibenzodioxin affects the expression of EGLN3 mRNA | CTD | PMID:22298810 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | EXP | | 6480464 | Tetrachlorodibenzodioxin results in increased expression of EGLN3 mRNA | CTD | PMID:21215274 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:732653 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of EGLN3 mRNA | CTD | PMID:19933214 |
| 2,3,7,8-tetrachlorodibenzodioxine | multiple interactions | ISO | RGD:732652 | 6480464 | [Estradiol co-treated with Tetrachlorodibenzodioxin] results in increased expression of EGLN3 mRNA | CTD | PMID:19619570 |
| 2,3,7,8-tetrachlorodibenzodioxine | increases expression | ISO | RGD:732652 | 6480464 | Tetrachlorodibenzodioxin results in increased expression of EGLN3 mRNA | CTD | PMID:19619570 |
| aflatoxin B1 | affects expression | ISO | RGD:732652 | 6480464 | Aflatoxin B1 affects the expression of EGLN3 protein | CTD | PMID:20106945 |
| aflatoxin B1 | increases expression | ISO | RGD:732652 | 6480464 | Aflatoxin B1 results in increased expression of EGLN3 mRNA | CTD | PMID:22100608 |
| alendronic acid | affects expression | EXP | | 6480464 | Alendronate affects the expression of EGLN3 mRNA | CTD | PMID:16079270 |
| ammonium chloride | affects expression | EXP | | 6480464 | Ammonium Chloride affects the expression of EGLN3 mRNA | CTD | PMID:16483693 |
| benazepril | increases expression | EXP | | 6480464 | benazepril results in increased expression of EGLN3 mRNA | CTD | PMID:14871019 |
| bisphenol A | increases expression | EXP | | 6480464 | bisphenol A results in increased expression of EGLN3 mRNA | CTD | PMID:15901920 |
| choline | multiple interactions | ISO | RGD:732653 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of EGLN3 gene | CTD | PMID:20938992 |
| cobalt atom | multiple interactions | ISO | RGD:732652 | 6480464 | [tungsten carbide binds to Cobalt] which results in increased expression of EGLN3 mRNA | CTD | PMID:20105288 |
| cobalt atom | multiple interactions | ISO | RGD:732652 | 6480464 | [tungsten carbide co-treated with Cobalt] results in increased expression of EGLN3 mRNA | CTD | PMID:18078969 |
| cobalt dichloride | increases expression | ISO | RGD:732652 | 6480464 | cobaltous chloride results in increased expression of EGLN3 mRNA | CTD | PMID:20105288 |
| cobalt dichloride | increases expression | ISO | RGD:732652 | 6480464 | cobaltous chloride results in increased expression of EGLN3 mRNA | CTD | PMID:19376846 PMID:20105288 |
| corticosterone | increases expression | EXP | | 6480464 | Corticosterone results in increased expression of EGLN3 mRNA | CTD | PMID:15755911 |
| cyclosporin A | decreases expression | ISO | RGD:732652 | 6480464 | Cyclosporine results in decreased expression of EGLN3 mRNA | CTD | PMID:20106945 |
| diethylstilbestrol | increases expression | ISO | RGD:732652 | 6480464 | Diethylstilbestrol results in increased expression of EGLN3 mRNA | CTD | PMID:19371625 |
| dioxygen | increases expression | ISO | RGD:732652 | 6480464 | Oxygen deficiency results in increased expression of EGLN3 mRNA | CTD | PMID:20042640 |
| dioxygen | increases expression | ISO | RGD:732652 | 6480464 | Oxygen deficiency results in increased expression of EGLN3 mRNA | CTD | PMID:20042640 PMID:22745725 |
| dioxygen | multiple interactions | ISO | RGD:732652 | 6480464 | deguelin inhibits the reaction [Oxygen deficiency results in increased expression of EGLN3 mRNA] | CTD | PMID:22745725 |
| dioxygen | increases expression | ISO | RGD:732653 | 6480464 | Oxygen deficiency results in increased expression of EGLN3 mRNA | CTD | PMID:20880076 |
| folic acid | multiple interactions | ISO | RGD:732653 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of EGLN3 gene | CTD | PMID:20938992 |
| heparin | multiple interactions | EXP | | 6480464 | Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of EGLN3 mRNA] | CTD | PMID:16401727 |
| hydrogen peroxide | multiple interactions | ISO | RGD:732652 | 6480464 | [Hydrogen Peroxide co-treated with Theophylline] results in increased expression of EGLN3 protein | CTD | PMID:18951874 |
| indole-3-methanol | affects expression | EXP | | 6480464 | indole-3-carbinol affects the expression of EGLN3 mRNA | CTD | PMID:21396975 |
| iron atom | increases expression | EXP | | 6480464 | Iron deficiency results in increased expression of EGLN3 mRNA | CTD | PMID:16629162 |
| L-ascorbic acid | multiple interactions | ISO | RGD:732652 | 6480464 | [Quercetin co-treated with Ascorbic Acid] results in increased expression of EGLN3 mRNA | CTD | PMID:17639512 |
| L-methionine | multiple interactions | ISO | RGD:732653 | 6480464 | [Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased methylation of EGLN3 gene | CTD | PMID:20938992 |
| lead diacetate | decreases expression | ISO | RGD:732653 | 6480464 | lead acetate results in decreased expression of EGLN3 mRNA | CTD | PMID:22609695 |
| N-nitrosodiethylamine | multiple interactions | EXP | | 6480464 | [Diethylnitrosamine co-treated with beta-Naphthoflavone] results in increased expression of EGLN3 mRNA | CTD | PMID:18164116 |
| N-nitrosodiethylamine | increases expression | EXP | | 6480464 | Diethylnitrosamine results in increased expression of EGLN3 mRNA | CTD | PMID:19638242 |
| nickel atom | increases expression | ISO | RGD:732653 | 6480464 | Nickel results in increased expression of EGLN3 mRNA | CTD | PMID:18922574 |
| nickel dichloride | increases expression | ISO | RGD:732652 | 6480464 | nickel chloride results in increased expression of EGLN3 mRNA | CTD | PMID:21455298 |
| nickel dichloride | affects expression | EXP | | 6480464 | nickel chloride affects the expression of EGLN3 mRNA | CTD | PMID:22110744 |
| paracetamol | affects expression | ISO | RGD:732653 | 6480464 | Acetaminophen affects the expression of EGLN3 mRNA | CTD | PMID:17562736 |
| perfluorooctanoic acid | increases expression | EXP | | 6480464 | perfluorooctanoic acid results in increased expression of EGLN3 mRNA | CTD | PMID:19162173 |
| phenobarbital | multiple interactions | ISO | RGD:732653 | 6480464 | NR1I3 protein affects the reaction [Phenobarbital results in increased expression of EGLN3 mRNA] | CTD | PMID:19482888 |
| phenobarbital | increases expression | ISO | RGD:732653 | 6480464 | Phenobarbital results in increased expression of EGLN3 mRNA | CTD | PMID:19482888 |
| phenylephrine | increases expression | EXP | | 6480464 | Phenylephrine results in increased expression of EGLN3 mRNA | CTD | PMID:18158353 |
| pirinixic acid | increases expression | ISO | RGD:732653 | 6480464 | pirinixic acid results in increased expression of EGLN3 mRNA | CTD | PMID:18301758 |
| pirinixic acid | decreases expression | ISO | RGD:732653 | 6480464 | pirinixic acid results in decreased expression of EGLN3 mRNA | CTD | PMID:18445702 |
| propiconazole | decreases expression | ISO | RGD:732653 | 6480464 | propiconazole results in decreased expression of EGLN3 mRNA | CTD | PMID:21278054 |
| quercetin | multiple interactions | ISO | RGD:732652 | 6480464 | [Quercetin co-treated with Ascorbic Acid] results in increased expression of EGLN3 mRNA | CTD | PMID:17639512 |
| raloxifene | affects expression | EXP | | 6480464 | Raloxifene affects the expression of EGLN3 mRNA | CTD | PMID:16079270 |
| ranitidine | multiple interactions | EXP | | 6480464 | Heparin inhibits the reaction [[Lipopolysaccharides co-treated with Ranitidine] results in increased expression of EGLN3 mRNA] | CTD | PMID:16401727 |
| ranitidine | multiple interactions | EXP | | 6480464 | [Lipopolysaccharides co-treated with Ranitidine] results in increased expression of EGLN3 mRNA | CTD | PMID:16401727 PMID:16415329 |
| ranitidine | multiple interactions | EXP | | 6480464 | [Lipopolysaccharides co-treated with Ranitidine] results in increased expression of EGLN3 mRNA | CTD | PMID:16415329 PMID:16401727 |
| rosiglitazone | increases expression | EXP | | 6480464 | rosiglitazone results in increased expression of EGLN3 mRNA | CTD | PMID:21515302 |
| theophylline | multiple interactions | ISO | RGD:732652 | 6480464 | [Hydrogen Peroxide co-treated with Theophylline] results in increased expression of EGLN3 protein | CTD | PMID:18951874 |
| troglitazone | decreases expression | EXP | | 6480464 | troglitazone results in decreased expression of EGLN3 mRNA | CTD | PMID:21515302 |
| ursodeoxycholic acid | decreases expression | EXP | | 6480464 | Ursodeoxycholic Acid results in decreased expression of EGLN3 mRNA | CTD | PMID:15885361 |
| zinc atom | affects expression | EXP | | 6480464 | Zinc affects the expression of EGLN3 mRNA | CTD | PMID:16413754 |
| zinc(0) | affects expression | EXP | | 6480464 | Zinc affects the expression of EGLN3 mRNA | CTD | PMID:16413754 |